Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Mid-range Performer
1395.2000 -4.10 (-0.29%)
NSE Sep 23, 2025 15:31 PM
Volume: 202.4K
 

1395.20
-0.29%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 8% YoY to | 751 crore (I-direct estimate: | 783 crore) mainly due to 9% growth in domestic formulations to | 335 crore (Idirect estimate: | 355 crore). Export formulations grew 6% YoY to | 234 crore (I-direct estimate: | 257 crore) EBITDA margins improved 182 bps YoY to 14.7% (I-direct estimate: 13.7%) on account of a strong gross margin performance. Gross margins increased 357 bps YoY to 66.2% (I-direct estimate: 62.0%) Net profit grew 66% YoY to | 45 crore (I-direct estimate: | 44 crore)...
Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr
More from Ipca Laboratories Ltd.
Recommended